NextFin News - Oura Health Oy, the Finnish pioneer of the smart ring market, has filed confidentially for an initial public offering in the United States, according to people familiar with the matter. The move marks a significant milestone for the wearable technology sector as Oura seeks to capitalize on a massive surge in consumer demand for discreet health-tracking devices. The company, which was valued at approximately $11 billion in a funding round led by Fidelity in late 2025, is working with investment banks to prepare for a listing that could occur as early as the second half of 2026.
The confidential filing allows Oura to keep its financial details private while it navigates the initial regulatory review process with the Securities and Exchange Commission. This strategy is common among high-growth tech firms looking to avoid revealing sensitive competitive data until they are closer to their debut. Oura’s trajectory has been steep; the company reportedly generated $1 billion in revenue in 2025, a 100% increase from the previous year, and CEO Tom Hale has publicly projected that sales could approach $2 billion by the end of 2026. This growth has been fueled by an aggressive expansion into retail giants like Amazon and Target, alongside the successful launch of the Oura Ring 4.
While the headline numbers suggest a dominant market position, the competitive landscape is shifting rapidly. Samsung’s entry into the smart ring space with the Galaxy Ring has introduced a formidable rival with vast distribution networks and deep pockets. Furthermore, rumors persist that Apple continues to explore the category, which would fundamentally alter the economics of the niche hardware market. Oura has responded by leaning heavily into its subscription model, which now accounts for roughly 20% of its total revenue. By charging users a monthly fee for detailed health insights, Oura is attempting to transition from a hardware-dependent manufacturer to a recurring-revenue software platform.
The valuation of $11 billion remains a point of debate among private market analysts. According to data from Sacra, Oura’s most recent valuation represents a significant premium over its late-2024 level of $5.2 billion. Some institutional investors have expressed caution regarding the sustainability of this multiple, noting that hardware-centric companies often struggle to maintain high valuations once the initial growth phase plateaus. A Bloomberg report in early 2026 indicated that Oura had planned a tender offer for existing investors at a 25% discount to its Series E price, a move typically intended to provide liquidity to early backers while acknowledging that the peak private valuation may have been ahead of the broader market's appetite.
Oura’s success is also tied to its ability to maintain a technological lead in biometric accuracy. The company has spent years refining its sensors for sleep tracking and heart rate variability, areas where it currently holds a perceived edge over multi-purpose smartwatches. However, the risk of commoditization is real. As sensor technology becomes cheaper and more accessible, Oura must prove that its proprietary algorithms and "readiness" scores provide enough value to justify both a $300-plus hardware purchase and a perpetual subscription. The upcoming IPO will serve as a definitive test of whether public investors view smart rings as a permanent fixture of the digital health ecosystem or a high-end accessory vulnerable to consolidation by Big Tech.
Explore more exclusive insights at nextfin.ai.